Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis
- 8 November 2007
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 47 (1), 133-142
- https://doi.org/10.1002/hep.21960
Abstract
A longitudinal, cohort study was performed to characterize the clinical features of patients with small‐duct primary sclerosing cholangitis (PSC) occurring with and without inflammatory bowel disease (IBD) and to determine the influence of IBD and the effect of ursodeoxycholic acid (UDCA) therapy on the course of the liver disease. Forty‐two patients with small‐duct PSC (14 women and 28 men; mean age, 36.7 ± 13.3 years) were followed for up to 24.9 years. At presentation, prevalence of signs of liver disease (none versus 35%, P = 0.002), gastroesophageal varices (5% versus 30%, P = 0.03), and stage III/IV disease (9% versus 45%, P = 0.008) were lower in those with IBD versus those without IBD. During follow‐up, 6 patients underwent liver transplantation, and another died of cirrhosis. Using the Cox proportional hazard analysis, concomitant IBD was not associated with liver death or transplant, whereas the revised Mayo risk score for PSC was the only prognostic factor associated with liver‐related outcomes (relative risk, 6.47; 95% confidence interval, 1.75‐137.5). UDCA (13‐15 mg/kg/day) therapy for an average of 40 months showed biochemical improvement (P < 0.001) in UDCA‐treated patients, while no significant change occurred in untreated patients. UDCA therapy had no effect on delaying progression of disease (relative risk, 0.95; 95% confidence interval, 0.38‐2.36). Conclusion: Small‐duct PSC often is recognized at an early stage in patients with IBD; however, IBD has no impact on long‐term prognosis. Although UDCA therapy improves liver biochemistries, it may not delay disease progression during the short period of treatment. (HEPATOLOGY 2008.)This publication has 22 references indexed in Scilit:
- Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasisNature Clinical Practice Gastroenterology & Hepatology, 2006
- Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitisJournal of Gastroenterology and Hepatology, 2005
- Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trialJournal of Hepatology, 2000
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999
- Primary sclerosing cholangitisHepatology, 1999
- Ursodiol for Primary Sclerosing CholangitisNew England Journal of Medicine, 1997
- Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study periodJournal of Hepatology, 1994
- The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosisHepatology, 1994
- Small-Duct Primary Sclerosing CholangitisSeminars in Liver Disease, 1991
- Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitisHepatology, 1981